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Hepatitis C virus (HCV) is the leading cause of chronic viral
hepatitis, affecting approximately 170 million people worldwide (8, 40). HCV coinfection with human immunodeficiency
virus (HIV) is also common, occurring overall in 25 to 30% of
HIV-positive persons (1). Individuals with chronic HCV infection are at high risk for the development of cirrhosis and
hepatocellular carcinoma. A pegylated interferon and ribavirin
combination is the standard therapy to treat hepatitis C but
suffers from limited efficacy (⬍50% antiviral response among
patients infected with the dominant genotype 1 HCV) and
severe side effects (18, 27). More efficacious and safer antiviral
drugs for effective treatment of hepatitis C are urgently
needed. A thorough understanding of the HCV life cycle will
likely provide novel targets for antiviral drug discovery and
development to control HCV infection.
HCV is an enveloped RNA virus containing a singlestranded, positive-sense RNA genome and is classified as a
Hepacivirus in the Flaviviridae family (11, 33). The viral RNA
genome carries a single open reading frame flanked by untranslated regions (UTRs) at both the 5⬘ and 3⬘ ends. The 5⬘
and 3⬘ UTRs contain cis-acting RNA elements important for
the initiation of HCV polyprotein translation and viral RNA
replication (24). Upon translation, the HCV polyprotein precursor is proteolytically processed by cellular peptidases and
viral proteases into at least 10 different viral proteins (C, E1,
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E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B). Studies
with subgenomic HCV RNAs demonstrated that the NS3 to
NS5B proteins, in association with intracellular membranes
and cellular proteins, are essential and sufficient for HCV
RNA replication in the cell (5, 14, 25). The newly synthesized
HCV proteins and RNA genome are assembled to form progeny HCV particles by undetermined mechanisms.
Our earlier work found that infectious HCV particles are
highly enriched in apolipoprotein E (apoE), which is a major
determinant of HCV infectivity and production in cell culture
(10). ApoE-specific monoclonal antibodies (MAbs) effectively
neutralized HCV infectivity, in a dose-dependent manner. The
knockdown of apoE expression by specific small interfering
RNA (siRNA) remarkably suppressed HCV production,
suggesting that apoE is also important for the formation of
infectious particles and/or egression (10). However, studies
by others suggested that HCV assembly and production are
dependent on microsomal transfer protein (MTP) and apolipoprotein B (apoB), both of which are essential components
required for the assembly and secretion of very-low-density
lipoproteins (VLDLs) (19, 21). In those studies, both apoBspecific siRNAs and MTP inhibitors were found to suppress
HCV production (19, 21). It was speculated that HCV shares
the same assembly and secretion pathway with VLDLs.
To define the roles of apoB and apoE in the formation of
HCV particles and egression, we developed a single-cycle
HCV growth assay. Using this assay system, we have demonstrated that apoE but not apoB is required for the infectivity
and formation of infectious HCV particles. First of all, apoBspecific MAb and polyclonal antibodies did not affect HCV
infection. Additionally, apoE-specific siRNA potently inhib-
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Our previous studies have found that hepatitis C virus (HCV) particles are enriched in apolipoprotein E
(apoE) and that apoE is required for HCV infectivity and production. Studies by others, however, suggested
that both microsomal transfer protein (MTP) and apoB are important for HCV production. To define the roles
of apoB and apoE in the HCV life cycle, we developed a single-cycle HCV growth assay to determine the
correlation of HCV assembly with apoB and apoE expression, as well as the influence of MTP inhibitors on the
formation of HCV particles. The small interfering RNA (siRNA)-mediated knockdown of apoE expression
remarkably suppressed the formation of HCV particles. However, apoE expressed ectopically could restore the
defect of HCV production posed by the siRNA-mediated knockdown of endogenous apoE expression. In
contrast, apoB-specific antibodies and siRNAs had no significant effect on HCV infectivity and production,
respectively, suggesting that apoB does not play a significant role in the HCV life cycle. Additionally, two MTP
inhibitors, CP-346086 and BMS-2101038, efficiently blocked secretion of apoB-containing lipoproteins but did
not affect HCV production unless apoE expression and secretion were inhibited. At higher concentrations,
however, MTP inhibitors blocked apoE expression and secretion and consequently suppressed the formation
of HCV particles. Furthermore, apoE was found to be sensitive to trypsin digestion and to interact with NS5A
in purified HCV particles and HCV-infected cells, as demonstrated by coimmunoprecipitation. Collectively,
these findings demonstrate that apoE but not apoB is required for HCV assembly, probably via a specific
interaction with NS5A.
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MATERIALS AND METHODS
Cell lines and cell culture. A highly HCV-permissive human hepatoma cell
line (6), Huh7.5, was generously provided by Charles M. Rice. Huh7.5 cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
fetal bovine serum (FBS), nonessential amino acids, penicillin, and streptomycin
(Invitrogen).
Production and purification of apoB-specific MAbs. A hybridoma cell line
producing apoB (464B1B3) blocking MAb was purchased from the American
Type Culture Collection (ATCC) and maintained in RPMI 1640 medium (Invitrogen) supplemented with 10% FBS. To make apoB-specific MAb, 50 g of
purified human apoB (Biodesign International, Saco, ME) emulsified with
Freund’s complete adjuvant (Sigma) was subcutaneously injected into female
RBF-DnJ mice (The Jackson Laboratory). Upon three subsequent booster immunizations at 10-day intervals, splenic lymphocytes were fused with P3X
myeloma cells by use of polyethylene glycol 4000 (Sigma). ApoB MAb-producing
hybridomas were selected and identified as previously described (10). The MAbs
were purified using a protein A antibody purification kit (Bio-Rad Laboratories).
The concentration of purified MAbs was determined by spectrophotometry.
Antibody neutralization of HCV infectivity. Huh7.5 cells in 12-well (for detection of HCV proteins) or 6-well (for quantification of HCV RNA) plates were
infected with HCV of genotype 2a (JFH1) at 37°C for 2 to 3 h. The HCVinfected cells were washed twice with phosphate-buffered saline (PBS) and then
incubated with 10% FBS-containing DMEM. For antibody neutralization of
HCV infectivity, HCV was incubated with increasing concentrations (0, 0.4, 2.0,
10, and 50 g/ml) of normal mouse immunoglobulin G (IgG), apoB, or apoE
antibody at room temperature for 1 h and then added to Huh7.5 cells (7, 10).
ApoB antibodies included polyclonal rabbit anti-apoB (Calbiochem) and goat
anti-apoB (Biodesign International), MAb 464B1B3 (23), and apoB MAb3 and
MAb4 (raised in our lab). ApoE MAb23 (10) was also included for comparison.
At 2 h postinfection (p.i.), the antibody-HCV mixture was removed, and the
HCV-infected cells were washed twice with PBS and then incubated with
DMEM containing 10% FBS. At 3 days p.i., cell culture medium was collected
and clarified by centrifugation to remove any cell debris. HCV-infected cells
were lysed and used for detection of HCV NS3 protein by Western blotting. The
level of HCV in the medium was determined by subsequent infection of Huh7.5
cells, and the levels of HCV NS3 protein and positive-strand RNA were detected
by Western blotting and an RNase protection assay (RPA), respectively (7, 10).
The HCV titer in the medium was determined by immunofluorescence staining
for NS3-positive cell foci and is reported in focus-forming units (FFU)/ml (7, 10).
Knockdown of apoB and apoE expression by specific siRNAs. SmartPool
siRNAs targeting apoB and apoE mRNAs were purchased from Dharmacon.
The most potent siRNAs identified from SmartPool siRNAs were chosen for
subsequent experiments. The siRNA targeting sequences for apoB and apoE
mRNAs were 5⬘-AGACAGAGCCGGAGCCCGA-3⬘ and 5⬘-AGACAGAGCC
GGAGCCCGA-3⬘, respectively. A nonspecific control (NSC) siRNA was also
purchased from Dharmacon. Huh7.5 cells were infected with HCV at a multiplicity of infection (MOI) of approximately 5 and then transfected with apoB,
apoE, or NSC siRNA, using Lipofectamine RNAiMax (Invitrogen). The mixture
of siRNA and RNAiMax was serially diluted with serum-free medium, from 50
nM to 0.4 nM. At 24 h p.i., the medium was collected and cleared by centrifugation to remove cells and cell debris. The infectivity of HCV secreted into the

medium was determined by subsequent infection of Huh7.5 cells. The levels of
both NS3 protein and positive-strand HCV RNA were determined by Western
blotting and RPA, respectively. Infectious HCV titers were determined by immunofluorescence assay (IFA) after serial dilution (7, 10). To isolate intracellular HCV particles, the HCV-infected cells were washed twice with 1⫻ PBS and
then collected by scraping into 1⫻ PBS. Intracellular HCV particles were prepared by freeze-thawing three times (20). Infectious titers of the intracellular
HCV particles were determined by IFA and reported in FFU. HCV virion RNA
(vRNA) in the medium and intracellular HCV particles were extracted with
Trizol LS reagent (Invitrogen) and quantified by a real-time quantitative reverse
transcription-PCR (qRT-PCR) method.
Construction of a siRNA-resistant apoE-expressing cDNA and ectopic apoE
expression. Five silent mutations (underlined in the oligonucleotide sequence of
mApoE/Up) were introduced into the siRNA targeting region of the apoE3
gene, using a QuikChange Lightning site-directed mutagenesis kit (Stratagene,
La Jolla, CA) and two synthetic oligonucleotides, mApoE/Up (5⬘-GCAAGCGGT
GGAGACGGAACCCGAACCGGAGCTGCGCCAGCAG-3⬘) and mApoE/Bt
(5⬘-CTGCTGGCGCAGCTCCGGTTCGGGTTCCGTCTCCACCGCTTGC-3⬘).
The resultant apoE3-expressing cDNA was confirmed by DNA sequence analysis
(Northwestern University Genomics Core, Chicago, IL) and was designated
pCMV6XL5/mApoE3. This plasmid DNA was used to determine whether
ectopic expression of apoE3 is able to substitute for the role of endogenous apoE
in HCV assembly. Initially, Huh7.5 cells in a 12-well plate were transfected with
either an NSC siRNA or apoE-specific siRNA at 50 nM. At 12 h posttransfection, the siRNA-transfected Huh7.5 cells were supertransfected with 1 g of
pCMV6XL5/mApoE3 DNA or the vector DNA as a control. Twelve hours after
DNA transfection, Huh7.5 cells were infected with HCV at an MOI of approximately 5. At 24 h p.i. (single-cycle virus growth), Huh7.5 cells were lysed in
RIPA buffer. The levels of HCV proteins were determined by Western blotting.
The cell culture medium was collected and used to measure the levels of apoE
expression (by Western blotting) and HCV infectivity. The HCV infectivity assay
was carried out by infecting naïve Huh7.5 cells in a six-well plate with the
collected cell culture medium. At 3 days p.i., total RNA was extracted with Trizol
from the HCV-infected cells and the levels of positive-strand HCV RNA were
determined by RPA.
Treatment with MTP inhibitors. The MTP inhibitor CP-346086 (9) was synthesized by ACME Bioscience (Belmont, CA), and BMS-2101038 (21, 39) was a
gift of Jin Ye (University of Texas Southwestern Medical Center). For multiplecycle virus growth, Huh7.5 cells were infected with HCV at an MOI of about 0.3.
For single-cycle HCV growth, Huh7.5 cells were infected with HCV at an MOI
of 5 at 37°C for 2 h. The HCV-infected cells were washed with PBS and then
incubated with DMEM containing 10% FBS and increasing concentrations of
CP-346086 or BMS-2101038. At 24 h p.i. (for single-cycle HCV growth) or 3 days
p.i. (for multiple-cycle HCV growth), the medium was collected and clarified by
centrifugation. HCV infectivity in the medium was determined by infection of
Huh7.5 cells, and the level of NS3 protein was determined by Western blotting.
HCV titers in the medium were determined by IFA and reported in FFU/ml.
Intracellular HCV particles were isolated from the HCV-infected cells by repeated freezing and thawing, followed by centrifugation to remove any debris, as
previously described (20). Infectious titers of intracellular HCV particles were
determined by IFA. The levels of HCV vRNA in the medium and in intracellular
HCV particles were quantified by qRT-PCR.
Western blot analysis. A lysate of HCV-infected cells was prepared by using
standard procedures (7). Twenty-five micrograms of total protein was resolved by
electrophoresis in a 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel, followed by transfer onto a nitrocellulose membrane. The level of HCV proteins
was determined by Western blotting, using an NS3- or NS5A-specific MAb, as
previously described (7). The ␤-actin protein was used as an internal control. To
quantify the levels of apoB and apoE, 12 l of cell culture medium was electrophoresed in 5% and 10% SDS-polyacrylamide gels (SDS-PAGE), respectively.
The apoB and apoE levels were determined by Western blotting using apoB
(Biodesign)- and apoE (MAb33)-specific antibodies (10). HCV E2 in virus particles was determined by IP and Western blotting, using E2-specific MAbs provided by Michael Diamond (Washington University). Both E2-specific MAbs
J6E2.1 and H77E2.7 were raised against soluble E2 proteins of the J6 and H77
strains of HCV, and both are IgG1 antibodies (Michelle Sabo and Michael
Diamond, unpublished results).
HCV RNA extraction and quantification by RPA. Total RNAs were extracted
from HCV-infected cells by use of Trizol reagent (Invitrogen). The level of
positive-strand HCV RNA in the cells was determined by RPA, using an
[␣-32P]UTP-labeled probe containing the negative-strand HCV 3⬘-UTR RNA,
as described previously (10). After digestion with RNase A/T1, RNA products
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ited the formation of infectious HCV particles, whereas HCV
production was unaffected by the siRNA-mediated knockdown
of apoB expression. Furthermore, two MTP inhibitors, CP346086 and BMS-2101038, efficiently blocked apoB secretion
but did not significantly affect HCV production prior to the
blockage of apoE expression/secretion. At higher concentrations, however, both MTP inhibitors blocked apoE secretion
and consequently suppressed the formation of infectious HCV
particles. To further understand the role of apoE in HCV
assembly, we carried out coimmunoprecipitation (co-IP) experiments and found that apoE-specific MAb pulled down
NS5A but not other HCV proteins from lysed HCV particles,
suggesting a specific interaction between apoE and NS5A during the formation of infectious HCV particles. Collectively, our
findings demonstrate that apoE but not apoB is required for
HCV assembly, probably via a specific interaction with NS5A.
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RESULTS
ApoB-specific antibodies do not neutralize HCV infectivity.
We have previously shown that infectious HCV particles are
enriched in apoE and that apoE-specific MAbs efficiently neutralized HCV infectivity in a dose-dependent manner, suggesting that apoE incorporated into HCV particles is required for
HCV infection (10). Several previous studies found that HCV
is associated with lipoproteins in the plasma of hepatitis C
patients (2, 3, 31, 32). Additionally, two recent studies suggested that apoB is important for HCV production in cell
culture (19, 21). To examine the role of apoB in HCV infection, apoB-specific MAbs and polyclonal antibodies were used
in HCV neutralization experiments. The commercially available apoB (46B1B3) blocking MAb was previously characterized (23). We also raised apoB-specific MAbs (apoB MAb3

and MAb4). Purified normal mouse IgG was used as a negative
control. HCV neutralization experiments were carried out by
mixing HCV with various amounts of antibodies prior to and
during virus infection. At 3 days p.i., the levels of HCV NS3
protein and positive-strand HCV RNA in the HCV-infected
cells were determined by Western blotting and RPA, respectively. Similar to normal mouse IgG, all apoB-specific MAbs
and polyclonal antibodies at up to 50 g/ml did not significantly reduce the level of HCV NS3 protein (Fig. 1A). Likewise, none of the apoB-specific antibodies affected the level of
positive-strand HCV RNA (data not shown). More importantly, HCV titers in the medium of HCV-infected cells in the
presence of increasing amounts of apoB-specific antibodies
during infection were unaffected (Fig. 1B). In contrast, apoE
MAb23 reduced the level of NS3 protein by 90% and lowered
the HCV titer by 3 orders of magnitude (1,000 times) at 50
g/ml, consistent with our previous findings (10). These results
demonstrate that apoE- but not apoB-specific antibodies can
neutralize HCV infectivity, suggesting that apoE but not apoB
is important for HCV infection.
Inhibition of HCV assembly by siRNA-mediated knockdown
of apoE expression. Besides an important role in HCV infection, apoE is also required for HCV production, as demonstrated by siRNA-mediated knockdown of apoE expression
and consequent suppression of HCV production (10). The
question remains of whether apoE plays a role in HCV assembly and/or egression. In our previous studies, we used a multiple-cycle virus growth assay, which could not discriminate the
role of apoE in infection from that in virion assembly/egression, since reduction of HCV infectivity upon the first round of
virus replication will lower HCV production (10). Thus, a single-cycle HCV growth assay is necessary in order to dissect
various steps of the HCV life cycle. Recently, we isolated an
infectious HCV that grows to high titer (nearly 107 FFU/ml),
which made it possible to determine the role of apoB and apoE
in HCV virion assembly/egression. The molecular basis underlying the higher growth rate (titer) of the cell culture-adapted
HCV has not been defined, although a number of amino acid
mutations were identified in C, E1, NS2, NS3, NS5A, and
NS5B, with most mutations clustered in NS5A (data not
shown). Our ongoing work to determine the role of adaptive
mutations in efficient virus growth will be reported separately.
Our previous studies suggested that one round of HCV replication requires about 24 h (7). Therefore, Huh7.5 cells were
infected with HCV at an MOI of approximately 5 at 37°C for
2 h and then transfected with apoB, apoE, or NSC siRNA at
various concentrations up to 50 nM. At 24 h p.i., cell culture
media were collected, and HCV-infected cells, with or without
siRNA transfection, were lysed in RIPA buffer. The levels of
apoB and apoE secreted into the medium were quantified by
Western blotting (Fig. 2). The apoB-specific siRNA efficiently
knocked down apoB expression, resulting in reductions of
apoB-100 of 50%, 80%, and 90% at concentrations of 2, 10,
and 50 nM, respectively (Fig. 2). Similarly, the apoE siRNA
specifically reduced apoE, by 40%, 60%, and 80%, at 2, 10, and
50 nM, respectively (Fig. 2). In contrast, the levels of both
apoB and apoE were unaffected by NSC siRNA (Fig. 2). The
effects of siRNA-mediated knockdown of apoB and apoE expression on viral RNA replication were determined by measuring the NS3 protein in the HCV-infected and siRNA-trans-
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were analyzed in a 6% polyacrylamide-urea (7.7 M) gel, visualized by autoradiography, and quantified by phosphorimager analysis (7, 26).
HCV vRNA extraction and quantification by qRT-PCR. HCV vRNA in the
medium and in intracellular HCV particles were extracted using Trizol LS
reagent (Invitrogen). The level of HCV vRNA was quantified by a qRT-PCR
method, using a SuperScript III Platinum one-step qRT-PCR kit following the
manufacturer’s instructions (Invitrogen). Oligonucleotides 2aF (5⬘-AGCCATG
GCGTTAGTATGAGTGTC-3⬘) and 2aR (5⬘-ACAAGGCCTTTCGCAACCC
AA-3⬘), complementary to sequences within the 5⬘ UTR, were used as primers.
The probe (5⬘-AAACCCACTCTATGCCCGGCCATTT-3), synthesized by Integrated DNA Technologies, contained 6-carboxyfluorescein at the 5⬘ end and
6-carboxytetramethylrhodamine at the 3⬘ end.
Determination of HCV titers by IFA. HCV titers were determined by an IFA
using an NS3-specific MAb, as previously described (10, 14). Briefly, HCV in the
medium was serially diluted (10⫻) and then used to infect naïve Huh7.5 cells on
coverslips in 24-well plates. At 3 days p.i., the number of cell FFU was determined by IFA.
Preparation and purification of HCV particles. HCV was prepared from
large-scale virus growth in 175-cm2 cell culture flasks. The HCV-containing
medium was cleared by passage through a 0.22-m filter unit (Corning). HCV
particles were concentrated by filtration through Centricon Plus-70 filter devices
(Millipore). The concentrated HCV was subjected to 10 to 60% sucrose gradient
sedimentation analysis, as previously described (7). A total of 12 fractions with 1
ml each were collected from the bottom to the top of the sucrose gradient. The
sucrose in fractions was removed by filtration through Amicon Ultra-15 filter
devices (Millipore). The resulting HCV was used for subsequent analysis of apoE
and NS5A interaction.
Trypsin digestion and detergent treatment of purified HCV particles. Purified
HCV particles were treated with trypsin (4 g/ml; Sigma) in 30 l of buffer (50
mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM CaCl2) in the absence or presence
of 1% Triton X-100 for 1 h at 37°C. The proteolysis reactions were terminated
by the addition of 1 mM phenylmethylsulfonyl fluoride and a 1/100 volume of
protease inhibitor cocktail (Roche) (41). HCV virion proteins were analyzed by
Western blotting, using apoE MAb33, HCV E2- and C-specific MAbs (7, 10).
Co-IP of NS5A with apoE in purified HCV particles and HCV-infected cells.
Co-IP of NS5A and apoE in purified HCV particles was performed using a co-IP
kit following the manufacturer’s instructions (Pierce). Briefly, purified apoE
MAb23, HCV E2 MAb, and apoB MAb were coupled to AminoLink Plus
coupling resin. HCV lysate was prepared by incubating purified HCV particles
with M-PER protein extraction reagent (Pierce) at room temperature for 10 min.
Purified HCV and HCV lysate were incubated with HCV E2-, apoB-, and
apoE-specific MAb-conjugated agarose resin overnight at 4°C. Upon elution,
HCV virion proteins were separated in a 10% SDS-PAGE gel and transferred to
a polyvinylidene difluoride (PVDF) membrane. For co-IP of apoE and NS5A in
the cells, a lysate of the HCV-infected cells was incubated with protein Gconjugated agarose beads (Invitrogen) bound with normal mouse IgG or apoBor apoE-specific MAb. Antibody binding to protein G-conjugated beads was
done by incubation with normal mouse IgG or apoB- or apoE-specific MAb at
room temperature for 5 h. The unbound antibodies were removed by being
washed with 1⫻ PBS three times. The antibody-bound agarose beads were then
incubated with 300 l of cell lysate at 4°C overnight. Upon co-IP, HCV core and
NSSA were detected by Western blotting using C- and NSSA-specific MAbs.
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FIG. 1. Effect of apoB-specific antibodies on HCV infectivity. HCV
was incubated with increasing concentrations (0, 0.4, 2.0, 10, and 50
g/ml) of normal mouse IgG, apoB polyclonal antibodies (rabbit and
goat anti-apoB [␣-ApoB]) or MAbs (464B1B3, apoB MAb3, and apoB
MAb4), and apoE MAb23 at room temperature for 1 h, followed by
infection of Huh7.5 cells. At 2 h p.i., the antibody-HCV mixture was
removed, and the HCV-infected cells were washed twice with PBS and
then incubated with DMEM containing 10% FBS. At 3 days p.i., the
level of HCV NS3 protein in the cells was determined by Western
blotting (A) and the titer of infectious HCV in the medium was
determined by serial dilution and immunofluorescence staining for
NS3-positive cell foci (B).

fected Huh7.5 cells. Similar to the NSC siRNA, neither apoB
nor apoE siRNA had any significant effect on viral RNA replication, as the level of NS3 remained unchanged (Fig. 3A).
These results are consistent with our previous finding that
siRNA-mediated knockdown of apoE expression did not affect

HCV RNA replication, as determined in a subgenomic HCV
RNA-harboring Huh7 cell line (10). To determine the effects
of apoB and apoE knockdown on HCV production, the media
of the HCV-infected and siRNA-transfected cells were used to
infect naïve Huh7.5 cells. The levels of NS3 protein and positive-strand HCV RNA were then determined by Western blotting and RPA, respectively (Fig. 3B and C). Similar to the
knockdown of apoE expression, the apoE-specific siRNA resulted in a remarkable reduction of infectious HCV in the
medium, as shown by 80% and 95% decreases of the NS3
protein at 10 and 50 nM, respectively (Fig. 3B). The apoE
siRNA lowered the level of positive-strand HCV RNA in the
subsequently infected cells by 60% and 90% at 10 nM and 50
nM, respectively (Fig. 3C). In contrast, apoB and NSC siRNAs
did not affect HCV production, even though the apoB-specific
siRNA knocked down apoB-100 expression by 90% (Fig. 2).
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FIG. 2. Knockdown of apoB and apoE expression by specific
siRNAs. (A) Determination of apoB and apoE secretion by Western
blotting. Huh7.5 cells were infected with HCV and then transfected
with apoB, apoE, or NSC siRNA at various concentrations, using
Lipofectamine RNAiMax (Invitrogen) following the manufacturer’s
instructions. At 24 h p.i., the levels of apoB and apoE secreted into the
medium were quantified by Western blotting using apoB (Biodesign)
and apoE antibodies, respectively. (B) Correlation of apoB-100 secretion and siRNA concentration. The levels of apoB-100 relative to the
control (without siRNA transfection) were converted to percentages of
the control (100%). The relative levels of apoB-100 (y axis) were
plotted against siRNA concentrations (x axis). (C) Correlation of apoE
level and siRNA concentration. The relative levels of apoE were plotted (y axis) against siRNA concentrations (x axis). The relative levels of
apoB and apoE shown in panels B and C are average values for three
independent experiments.
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FIG. 3. Effects of siRNA-mediated knockdown of apoB and apoE
expression on HCV replication and production. Huh7.5 cells were
infected with HCV at an MOI of 5 and then transfected with apoB,
apoE, or NSC siRNA as described in the legend to Fig. 2. At 24 h p.i.,
the medium was collected and cells were lysed in RIPA buffer. (A) Detection of NS3 protein in HCV-infected and siRNA-transfected cells
by Western blotting using an NS3-specific MAb. (B and C) Influence
of apoB and apoE siRNAs on HCV production. HCV in the medium
of HCV-infected and siRNA-transfected cells was used to infect naïve
Huh7.5 cells. The levels of NS3 protein (B) and positive-strand HCV
RNA (C) were determined by Western blotting and RPA, respectively,
as described in Materials and Methods. (D) Quantification of infectious HCV by serial dilution and IFA. HCV in the medium was serially
diluted and used to infect naïve Huh7.5 cells on coverslips. The titers
of infectious HCV were determined in FFU/ml as described for Fig.
1B. The titers of infectious HCV were plotted against siRNA concentrations. (E) Correlation of HCV vRNA level in the medium with
siRNA concentration. HCV vRNA in the medium was extracted with
Trizol reagent and quantified by real-time RT-PCR. The HCV vRNA
level was calculated as a percentage of the control level (without
siRNA). (F) Correlation of intracellular HCV titers with siRNA concentrations. Intracellular HCV particles were prepared from HCVinfected and siRNA-transfected Huh7.5 cells as described in Materials
and Methods. Intracellular HCV titers were determined in the same
way as for panel D. The titers of intracellular HCV were plotted
against siRNA concentrations. The means ⫾ standard deviations derived from three independent experiments were used for panels D to
F. White bars, NSC siRNA; gray bars, apoB siRNA; black bars, apoE
siRNA.
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Additionally, infectious HCV titers were proportionally lowered by increasing concentrations of the apoE-specific siRNA,
resulting in a 50-fold reduction of infectious HCV at 50 nM.
However, the apoB and NSC siRNAs had no effect on the
production of infectious HCV (Fig. 3D). These findings demonstrate that apoE but not apoB is required for the formation
of infectious HCV.
To further determine whether apoE is required for HCV
assembly and/or egression, the levels of infectious HCV particles and HCV vRNA in the medium and in intracellular HCV
particles were determined by IFA and a qRT-PCR method,
respectively. HCV vRNA reflects all HCV particles, including
infectious and noninfectious ones. Intracellular HCV particles
were prepared by repeated freezing and thawing of the HCVinfected and siRNA-transfected cells, followed by centrifugation to remove any debris, as previously described (10). Like
the case for infectious HCV, the level of HCV vRNA in the
medium was decreased in proportion to the reduction of apoE
expression, with about 60% reduction at 50 nM siRNA (Fig.
3E). However, apoB and NSC siRNAs did not influence the
level of HCV vRNA in the medium, demonstrating that apoB
is not required for HCV assembly/egression. Similarly, infectious titers of intracellular HCV particles were decreased ⬎10fold (Fig. 3F), consistent with the findings derived from the
multiple-cycle HCV growth assay (10). Likewise, the level of
HCV vRNA derived from intracellular HCV particles was
decreased 60% at 50 nM apoE siRNA (data not shown).
Again, apoB and NSC siRNAs did not affect the infectious
titers and vRNA levels of intracellular HCV particles (Fig. 3F
and data not shown). Taken together, these findings demonstrate that apoE but not apoB is required for HCV assembly in
the cell.

VOL. 83, 2009

12685

FIG. 4. Ectopic expression of apoE restored HCV production,
which was otherwise blocked by siRNA-mediated knockdown of endogenous apoE expression. Huh7.5 cells in 12-well plates were transfected with 50 nM of apoE or NSC siRNA. At 12 h posttransfection,
pCMV6XL5/mApoE or vector DNA was transfected into cells with
DMRIE-C (Invitrogen). After 12 h of incubation, Huh7.5 cells were
infected with HCV at an MOI of approximately 5. At 24 h p.i., the
medium was collected and cells were lysed in RIPA buffer. The medium was used for determinations of apoE levels and infectivity (HCV
production). (A) Determination of levels of apoE secretion in the
medium and of NS3 protein in the cells by Western blotting. Western
blot analysis of apoE and HCV NS3 was performed as described in the
legends to Fig. 2A and 3, respectively. (B and C) Restoration of HCV
production by ectopic expression of apoE. HCV in the medium of
siRNA-transfected or both siRNA- and apoE cDNA-transfected cells
was used to infect naïve Huh7.5 cells. At 3 days p.i., the levels of NS3
protein (B) and positive-strand HCV RNA (C) were determined by
Western blotting and RPA, respectively. The levels of positive-strand
HCV RNA were quantified by phosphorimager analysis and converted
into percentages of the control level, considering the level of HCV
RNA without siRNA and apoE-expressing DNA as 100%. Numbers at
the top of panels A and B and below panel C indicate the concentration of siRNA and the amount of DNA used in experiments.
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To exclude a possible off-target effect of apoE siRNA on
HCV assembly, we sought to determine whether ectopic expression of apoE would be able to restore HCV production in
Huh7.5 cells with knockdown of endogenous apoE expression.
A variant apoE-expressing cDNA (pCMV6XL5/mApoE) was
constructed by introducing five silent nucleotide mutations into
the siRNA targeting region. These nucleotide mutations do
not change amino acids but instead disrupt the complementarity between apoE mRNA and the siRNA, therefore evading
the siRNA-mediated destruction of apoE mRNA. As shown in
Fig. 4A, apoE-specific siRNA efficiently reduced apoE expression and secretion. However, transfection of the apoE-expressing DNA into Huh7.5 cells with the siRNA-mediated knockdown of endogenous apoE expression resulted in similar levels
of apoE in parental cells and cells transfected with NSC siRNA
(Fig. 4A), indicating that apoE expressed ectopically was not
affected by siRNA. Similar to the above findings, apoE siRNA
and ectopic expression of apoE did not affect HCV replication,
as shown by similar levels of HCV NS3 protein in the transfected cells (Fig. 4A). Strikingly, ectopic expression of apoE
fully restored HCV production, as demonstrated by similar
levels of both HCV NS3 protein and positive-strand RNA in
Huh7.5 cells infected with HCV derived from the apoE
siRNA- and cDNA-transfected cells compared to those in parental cells or cells transfected with NSC siRNA (Fig. 4B and
C). These findings demonstrate that apoE is truly required for
the formation of infectious HCV particles.
Effects of MTP inhibitors on formation of HCV particles. To
confirm the findings derived from the above experiments with
siRNAs, two MTP inhibitors, CP-346086 and BMS-2101038,
were used to block the assembly and secretion of apoB-containing lipoproteins. MTP is essential for the assembly and
secretion of apoB-containing lipoproteins (22). Previous studies by others suggested that the blockade of VLDLs by MTP
inhibitors suppresses HCV production and maturation (19,
21). To verify the role of apoB in HCV assembly/egression, a
multiple-cycle HCV growth assay was initially used to determine the effects of CP-346086 on apoB secretion and HCV
production. CP-346086 is a potent MTP inhibitor, with a 50%
effective concentration of 2.6 nM (9). Huh7.5 cells were infected with HCV and then incubated with CP-346086 at various concentrations for 3 days. At concentrations of up to 1 M,
CP-346086 resulted in a full blockade of apoB-100 secretion
(Fig. 5A and C). However, it did not significantly affect apoE
secretion, consistent with a recent report that an MTP inhibitor completely blocked apoB but did not affect apoE secretion
(16). Contrary to previous reports (19, 21), CP-346086 did not
affect HCV production at concentrations up to 1 M, as shown
by similar levels of NS3 protein (Fig. 5B and C) and positivestrand HCV RNA (data not shown) in the Huh7.5 cells infected with HCV derived from CP-346086-treated cells. Likewise, infectious HCV titers, which were determined by IFA,
remained unchanged (Fig. 5D), even though apoB-100 secretion was completely blocked by CP-346086 at 1 M (Fig. 5A
and C). When tested at higher concentrations (3.125 to 25
M), however, CP-346086 inhibited apoE secretion in a dosedependent manner, reducing apoE secretion by 85% at 25 M
(Fig. 6A and C). As a consequence, HCV production was
markedly suppressed, as determined by a proportional decrease of up to 90% of NS3 protein (Fig. 6B) and positive-
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FIG. 6. Suppression of apoE secretion and HCV production by
CP-346086 at high concentrations in multiple-cycle HCV growth assay.
Huh7.5 cells were infected with HCV at an MOI of 0.3 and then
treated with CP-346086 at various concentrations from 3.125 to 25 M.
After 3 days p.i., the medium was collected for determination of the
levels of apoB-100 and apoE secretion and HCV production. (A) Levels of apoB-100 and apoE secretion. ApoB and apoE in the medium
were detected by Western blotting. (B) Determination of infectious
HCV by infectivity assay. HCV in the medium was used to infect naïve
Huh7.5 cells. At 3 days p.i., NS3 was detected by Western blotting.
(C) Correlation of apoB and apoE with HCV production. The data
shown in panels A and B were quantified and converted to relative
levels of apoB, apoE, and NS3 as percentages of the control values.
Values are means ⫾ standard deviations derived from three experiments. (D) Determination of infectious HCV titers by IFA. Infectious
HCV titers (log FFU/ml) were plotted against CP-340686 concentrations (M).
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FIG. 5. Effect of CP-346086 at low concentrations on apoB and
apoE secretion and HCV production in multiple-cycle HCV growth
assays. Huh7.5 cells were infected with HCV at an MOI of 0.3 and then
incubated with DMEM containing CP-346086 at concentrations varying from 0.008 to 1 M. After 3 days p.i., the medium was collected for
determination of apoB and apoE secretion and HCV production.
(A) Determination of apoB and apoE secretion by Western blotting.
(B) Determination of infectious HCV by infectivity assay. HCV in the
medium was used to infect naïve Huh7.5 cells. At 3 days p.i., the level
of HCV NS3 protein was determined by Western blotting. (C) Correlation of apoB-100 and apoE secretion with HCV production. The
levels of apoB-100, apoE, and NS3 in panels A and B were quantified
and converted to percentages of the control levels, considering the
levels of apoB-100, apoE, and NS3 in the absence of CP-346086 as
100%. Relative levels of apoB-100, apoE, and NS3 were plotted
against concentrations of CP-346086. (D) Determination of infectious HCV titers by IFA. Infectious HCV in the medium of HCVinfected and inhibitor-treated cells was titrated and quantified by
IFA as FFU/ml.
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FIG. 7. Effect of CP-346086 on HCV production in single-cycle
HCV growth assays. Huh7.5 cells were infected with HCV at an MOI
of 5 at 37°C for 2 h and then treated with CP-346086 at concentrations
varying from 0.0016 to 25 M. At 24 h p.i., the medium was collected
for determination of the levels of apoB, apoE, and infectious HCV,
while cells were harvested for preparation of intracellular HCV particles. (A) Effect of CP-346086 on apoB and apoE secretion and production of infectious HCV. ApoB-100 and apoE in the medium were
detected by Western blotting. Infectious HCV in the medium was
determined by infectivity assay, as described for Fig. 3 to 6. HCV NS3
protein in the subsequently infected Huh7.5 cells was detected by
Western blotting. (B) Correlation of apoB-100 and apoE secretion
with level of infectious HCV. The levels of apoB-100, apoE, and NS3
represent the means ⫾ standard deviations derived from three different experiments, as shown in panel A. Relative levels of apoB-100,
apoE, and NS3 were calculated as percentages of the control values.
(C) Determination of infectious HCV titers by IFA. (D) HCV vRNA
level relative to control level in the medium. The extraction and quantification of HCV vRNA in the medium were performed as described
in the legend to Fig. 3. (E) Infectious titers of intracellular HCV
particles determined by IFA. Intracellular HCV titers were plotted
against CP-346086 concentrations (M).
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strand RNA (data not shown) at 25 M CP-346086 in the
Huh7.5 cells that were infected with HCV derived from CP340686-treated cells. The reduction of infectious HCV paralleled the decrease of apoE but not apoB secretion (Fig. 6C).
CP-346086 reduced infectious HCV titers by up to 3 orders of
magnitude (3 log) at concentrations from 3.125 to 25 M (Fig.
6D). These findings demonstrate that suppression of HCV
production by CP-346086 is due to the blockade of apoE but
not apoB secretion, unlike the case in previous reports (19, 21).
To verify that apoE but not apoB is required for the formation of infectious HCV particles, we repeated the experiments with MTP inhibitors, but using a single-cycle HCV
growth assay. Huh7.5 cells were infected with HCV at a high
MOI (MOI of 5) and then incubated with various concentrations (0.0016 to 25 M) of CP-346086 for 24 h. Like the
results obtained with the multiple-cycle HCV growth assay,
CP-346086 remarkably reduced apoB-100 secretion, with a
complete blockade of apoB-100 secretion at 0.2 M, but did
not affect HCV production (Fig. 7A). At concentrations above
0.2 M, however, it blocked apoE secretion in a dose-dependent manner and consequently decreased HCV production by
up to 70% (Fig. 7A). Infectious HCV titers were lowered by up
to 1.5 log, in proportion to increasing concentrations up to 25
M (Fig. 7C). The reduction of HCV production was in parallel with the decrease of apoE but not apoB secretion seen
with CP-346086 (Fig. 7B). The level of HCV vRNA in the
medium (Fig. 7D) was significantly reduced by CP-346086 only
at higher (1 M and above) concentrations. Also, the infectious titer of intracellular HCV was lowered by nearly 1.5
log (Fig. 7E). Using the single-cycle HCV growth assay, we
also tested another MTP inhibitor, BMS-2101038, which was
previously reported to inhibit HCV production (21). BMS2101038 is a more potent MTP inhibitor than CP-346086, with
a 50% inhibitory concentration of 0.5 nM (39). Similar to
CP-346086, BMS-2101038 completely inhibited apoB secretion
at 20 nM but did not influence HCV production. At higher
concentrations, it blocked apoE secretion and therefore suppressed HCV production (Fig. 8A). Again, the suppression of
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HCV production superimposed the reduction of apoE but not
apoB secretion (Fig. 8B). Infectious HCV titers and the levels
of HCV vRNA in the medium and in intracellular HCV particles were reduced by BMS-2101038 only at concentrations
higher than 100 nM (data not shown), consistent with the
decrease of apoE secretion. All of these findings demonstrate
that suppression of HCV assembly by MTP inhibitors was due
to the blockage of apoE but not apoB secretion.
To exclude a possible inhibition of HCV RNA replication by
MTP inhibitors, the levels of positive-strand HCV RNA in the
HCV-infected and MTP inhibitor-treated Huh7.5 cells were
determined by RPA. As shown in Fig. 9, neither CP-346086
nor BMS-2101038 had any effect on the level of HCV RNA,
demonstrating that MTP inhibitors did not inhibit HCV RNA
replication. Therefore, the reduction of HCV particles by MTP
inhibition was due to the blockade of apoE secretion, which
consequently suppressed the formation of HCV particles.
Biochemical analysis of apoE in HCV particles by trypsin
digestion and IP. To determine the localization of apoE in
HCV particles, a trypsin digestion experiment was carried out.
Purified HCV particles were incubated with trypsin in the
absence or presence of 1% Triton X-100 to disrupt the virus

FIG. 9. Effects of MTP inhibitors on HCV RNA replication. HCV
infection and treatment with MTP inhibitors were the same as those
described in the legends to Fig. 7 and 8. At 24 h p.i., total RNAs in the
HCV-infected and MTP inhibitor-treated Huh7.5 cells were extracted
with Trizol reagent. The levels of positive-strand HCV RNA were
determined by RPA, using a radiolabeled RNA probe containing the
negative-sense HCV 3⬘ UTR as described in Materials and Methods.
The level of ␤-actin mRNA was used as a control for normalization of
the amounts of total RNA used between samples. The concentrations
of MTP inhibitors are indicated at the top. RNA probes and products
are highlighted by arrows on the right. Mock, naive Huh7.5 cells
without HCV infection.

envelope. Upon trypsin digestion, apoE and HCV C (capsid)
and E2 (envelope) proteins were detected by Western blotting
using specific MAbs. Both apoE and HCV E2 were sensitive to
trypsin digestion in the presence or absence of detergent treatment. It is not clear why E2 is less sensitive than apoE to
trypsin (Fig. 10A). It is possible that protein folding and/or
glycosylation may influence the sensitivity to trypsin digestion.
In contrast, HCV C was resistant to trypsin digestion but became sensitive to trypsin when the viral envelope was disrupted
by treatment with Triton X-100 (Fig. 10A). These results suggest that apoE is likely exposed on the viral envelope, similar
to HCV E2 protein. Consistent with these observations, an
apoE-specific MAb precipitated HCV particles, like HCV E2specific MAb did (Fig. 10B), whereas apoB-specific MAb
failed to do so. Interestingly, NS5A was also detected in the
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FIG. 8. Effect of BMS-2101038 on HCV production in single-cycle
HCV growth assays. Huh7.5 cells were infected with HCV at an MOI
of 5 and then incubated with DMEM containing various concentrations of BMS-2101038. At 24 h p.i., the medium was collected and used
to determine the levels of apoB-100 and apoE secretion and HCV
production. (A) Levels of apoB and apoE determined by Western
blotting. ApoB-100 and apoE in the medium were detected by Western
blotting using apoB and apoE MAbs, respectively. HCV NS3 in
Huh7.5 cells that were infected with medium derived from HCVinfected and BMS-2101038-treated cells was detected by Western blot
analysis. (B) Correlation of apoB-100 and apoE secretion with HCV
production. The levels of apoB-100, apoE, and NS3 relative to the
control levels (without inhibitor treatment) were converted from the
data shown in panel A and plotted against concentrations of BMS2101038.
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apoE and E2 MAb affinity-purified HCV particles, similar to
the HCV C protein (Fig. 10B). Collectively, these findings
suggest that apoE is likely a structural component of HCV
particles.
Interaction of apoE with NS5A in HCV-infected cells and in
HCV particles. To further understand the molecular basis underlying the importance of apoE in HCV assembly, co-IP experiments were performed to examine whether apoE interacts
with a viral protein(s) in HCV particles and/or in HCV-infected cells. Initially, lysed HCV particles were incubated separately with apoB-, apoE-, and HCV protein-specific MAbs.
As shown in Fig. 11A, an apoE-specific MAb specifically coprecipitated NS5A but not other viral proteins (data not
shown), consistent with the previous finding that apoE and
NS5A interact with each other, as shown by a yeast two-hybrid
system (15). HCV E2- and apoB-specific MAbs were unable to
coprecipitate NS5A. In HCV-infected Huh7.5 cells, NS5A was
also coprecipitated by an apoE- but not apoB-specific MAb or
normal mouse IgG (Fig. 11B). In contrast, apoE failed to
precipitate NS5A when supernatants of subgenomic HCV replicon cells were used in the co-IP experiments (data not
shown). These data suggest that the requirement of apoE for
HCV production is probably through a specific interaction with
NS5A during the process of HCV assembly.
DISCUSSION
We have previously shown that HCV grown in cell culture
was enriched in apoE and that HCV infectivity was closely
correlated with the level of apoE present in HCV particles
(10). ApoE-specific MAbs neutralized HCV infectivity by
nearly 90% and caused a reduction of infectious HCV titer of
up to 4 orders of magnitude (10,000-fold). Additionally, our
earlier work demonstrated that apoE is critically important for

FIG. 11. Determination of apoE and NS5A interaction by co-IP.
(A) Co-IP of NS5A with apoE in HCV particles. Purified HCV particles were lysed by treatment with M-PER protein extraction reagent
(Pierce). The resulting HCV lysate was subjected to co-IP using apoE-,
E2-, and apoB-specific MAbs as described in Materials and Methods.
(B) Co-IP of NS5A with apoE in HCV-infected cells. A lysate of naïve
or HCV-infected Huh7.5 cells was incubated with protein G-conjugated agarose beads (Invitrogen) bound with normal mouse IgG or
apoB- or apoE-specific MAb. Upon extensive washing, precipitated
proteins were separated by 10% SDS-PAGE and then transferred onto
a PVDF membrane. HCV NS5A protein was subsequently detected by
Western blotting using an NS5A-specific MAb.

HCV production. Knockdown of apoE expression by an apoEspecific siRNA resulted in reductions of infectious HCV in the
cells and in the medium by 10- and 100-fold, respectively (10).
These earlier findings suggest that apoE has dual functions in
cell entry (infection) and in formation and/or release of progeny HCV particles (assembly/egression). However, the previous findings were derived from multiple-cycle HCV growth
assays using a low MOI of HCV for infection, in which infection and replication are coupled (10). Thus, the impairment of
HCV infectivity by the lack of apoE could have resulted in a
subsequent reduction of HCV production upon multiple
rounds of HCV replication. In the present study, we used a
single-cycle virus growth assay which measured only one round
of HCV replication. In this report, we provide substantial evidence to demonstrate that apoE is likely a structural component of infectious HCV and plays an essential role in the
formation of infectious HCV particles. First of all, knockdown
of apoE expression by a specific siRNA resulted in a reduction
of HCV by 50 times in a single round of virus replication (Fig.
2 and 3A). More importantly, HCV particles released into the
medium as well as intracellular HCV particles were equally
suppressed by siRNA-mediated downregulation of apoE expression (Fig. 3). However, the reduction of HCV production
resulting from the siRNA-mediated knockdown of endogenous
expression of apoE could be restored fully by ectopic expression of apoE (Fig. 4). Additionally, MTP inhibitors suppressed
HCV production only when they blocked apoE production
and/or secretion (Fig. 6, 7, and 8). Suppression of HCV production by MTP inhibitors was superimposed with the reduction of apoE but not apoB secretion (Fig. 6C, 7B, and 8B),
demonstrating that HCV assembly and maturation require
apoE but not VLDLs, in which apoB is a major component.
Furthermore, biochemical analysis of purified HCV particles
by trypsin digestion and IP suggested that apoE is a structural
component of infectious HCV. Similar to our previous finding
(10), apoE- but not apoB-specific MAb could precipitate HCV
particles. More significantly, apoE was sensitive to protease
digestion, similar to HCV E2, suggesting that apoE is likely
exposed on the viral envelope. This hypothetical topology of
apoE explains its dual functions in HCV entry and virion
assembly. Of course, the ultimate proof for the localization of
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FIG. 10. Biochemical analysis of apoE in HCV particles. (A) Sensitivity of apoE to trypsin digestion. The preparation and purification
of HCV particles were described in Materials and Methods. Purified
HCV was treated with 4 g/ml of trypsin (Sigma) in the absence or
presence of 1% Triton X-100 at 37°C for 1 h. Trypsin reactions were
terminated by the addition of 1 mM phenylmethylsulfonyl fluoride and
a 1/100 volume of protease inhibitor cocktail (Roche). HCV C, E2, and
apoE were detected by Western blotting using an ECL substrate
(Pierce) and apoE-, C-, and E2-specific MAbs. (B) IP of HCV particles. HCV E2-, apoB-, and apoE-specific MAbs were individually coupled to AminoLink Plus coupling resin (Pierce). The antibody-conjugated resin was then incubated with purified HCV particles at 4°C
overnight. Upon elution, proteins of HCV particles were separated by
10% SDS-PAGE, followed by transfer of proteins onto a PVDF membrane. HCV core and NS5A proteins were detected by Western blotting.
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sensitivities of apoB and apoE to MTP inhibitors. Our findings
are consistent with those recently reported by others showing
that an MTP inhibitor completely suppressed apoB but had no
effect on apoE secretion (16). It is possible that high concentrations of MTP inhibitors may act on a different pathway from
the MTP pathway, resulting in apoE reduction. MTP inhibitors
at high concentrations are toxic to cells after long incubations
(data not shown). It will be interesting to determine which
cellular proteins are involved in apoE assembly and secretion,
which may present a novel target(s) for antiviral drug discovery
and development for controlling HCV infection.
The question remains of how apoE mediates two distinct
processes, cell entry and virion assembly, in the HCV life cycle.
ApoE is a 34-kDa (299 amino acids) apoprotein containing a
22-kDa N-terminal domain (residues 1 to 191) that is recognized by receptors and a 10-kDa C-terminal domain (residues
222 to 299) that interacts with phospholipids (29, 30, 38).
Based on its structure and roles in lipoprotein homeostasis, it
is conceivable that the receptor-binding domain of apoE may
mediate HCV infection, while the C-terminal domain associated with lipids is likely involved in HCV assembly. Our studies
have found that apoE interacts with HCV NS5A in the cell and
in HCV particles, suggesting that a specific protein-protein
interaction between apoE and NS5A may determine the outcome of HCV assembly. Supportive of this concept, recent
genetic studies have demonstrated that NS5A also functions in
HCV assembly/production, besides its important role in viral
RNA replication (4, 34). Domain III of NS5A was found to be
essential for HCV production even though it is not critical to
viral RNA replication (4). More interestingly, a single mutation at a phosphorylation site in domain III of NS5A ablated
HCV production, although it had no effect on viral RNA
replication (34). Based on these findings, we believe that the
apoE-NS5A interaction is important for the formation of HCV
particles and represents another unique target for antiviral
drug discovery against HCV infection. Future studies are warranted to determine how apoE and NS5A interact with each
other and whether mutations disrupting the apoE-NS5A interaction will result in an ablation of HCV assembly.
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ERRATUM
Apolipoprotein E but Not B Is Required for the Formation
of Infectious Hepatitis C Virus Particles
Jieyun Jiang and Guangxiang Luo
Department of Microbiology, Immunology and Molecular Genetics, University of
Kentucky College of Medicine, Lexington, Kentucky 40536
Volume 83, no. 24, p. 12680–12691, 2009. Page 12681, column 1, lines 9 to 7 from the bottom: “The siRNA targeting sequences
for apoB and apoE mRNAs were 5⬘-AGACAGAGCCGGAGCCCGA-3⬘ and 5⬘-AGACAGAGCCGGAGCCCGA-3⬘, respectively.” should read “The siRNA targeting sequences for apoB and apoE mRNAs were 5⬘-GCAAGCAAGUUGGCAAGUA-3⬘
and 5⬘-AGACAGAGCCGGAGCCCGA-3⬘, respectively.”
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